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The cell cycle is the cascade of events that allows a growing cell to duplicate all its components and split into two daughter cells.
Cell cycle progression is mediated by the activation of a highly conserved family of protein kinases, the cyclin-dependent kinases
(CDKs).CDKsarealsoregulatedbyrelatedproteinscalledcdkinhibitorsgroupedintotwofamilies:theINK4inhibitors(p16,p15,
p19, and p18) and the Cip/Kip inhibitors (p21, p27, and p53). Several studies report the importance of cell-cycle proteins in the
pathogenesis and the prognosis of lung cancer. This paper will review the most recent data from the literature about the regulation
of cell cycle. Finally, based essentially on the data generated in our laboratory, the expression, the diagnostic, and prognostic
signiﬁcance of cell-cycle molecules in lung cancer will be examined.
1.Introduction
Lung cancer remains a major health challenge in the
world. Despite improvements in staging and the integrated
application of surgery, radiotherapy, and chemotherapy, the
5-year survival rate for individuals with lung cancer is only
about 15% [1]. Histologically, 80% of the lung cancers are
diagnosed as non-small-cell lung cancer (NSCLC), whereas
the remaining 20% of cases are diagnosed as small-cell
lung cancer (SCLC). On the basis of cell morphology,
adenocarcinoma and squamous cell carcinoma are the most
common types of NSCLC. The current staging system for
NSCLC is based upon the size and location of the primary
tumor (T), the involvement of regional lymph nodes (N),
and the presence of distant metastases (M) [1]. The standard
treatment of patients with stage I NSCLC (T1-2, N0, M0)
is resection of the primary tumor alone (no adjuvant
therapy) [2]. Survival for patients with stage I disease ranges
between 40 and 70%, and the failure is due to distant recur-
rences [3]. This suggests that a signiﬁcant proportion of
patients with stage I NSCLC may actually be understaged.
Therefore, if correctly identiﬁed, these patients may beneﬁt
from adjuvant therapy in addition to resection, with a
predictable improvement in the survival rates. Indeed, to
identify patients with stage I NSCLC who might beneﬁt from
adjuvant therapy, investigators have attempted to identify
factors predicting poor prognosis. These studies included
analysis of performance status, histologic subtype, size of the
primary tumor, the degree of tumor diﬀerentiation, mitotic
rate, and evidence of lymphatic or vascular invasion [4–8].
However, all of these factors have failed, to date, to precisely
identify a group of stage I patients who would beneﬁt from
adjuvant therapy. Cigarette smoking remains the main risk
factor for lung cancer, accounting for about 90% of the cases
in men and 70% of the cases in women [9].
Our research group has investigated in the last years the
possible involvement of several molecular mechanisms, such
as cell cycle and apoptosis regulators, oncogenes and tumor
suppressor genes, cell adhesion molecules, in the pathogen-
esis and progression of lung cancer [10–20]. Goal of this
paper is to summarizez some of the most recent ﬁndings
about the regulation of cell cycle and about the role of cell-
cycle proteins in lung-cancer pathogenesis and progression.2 Pathology Research International
2. Cell Cycle
The cell cycle is the cascade of events that allows a growing
cell to duplicate all its components and split into two daugh-
ter cells; it consists of four distinct phases: G1 phase, S phase,
G2 phase (collectively known as interphase), and M phase.
High ﬁdelity duplication of DNA in each cell during the S
phase and the proper migration of the duplicated chromo-
somes in mitosis are highly regulated processes.
Cyclins and cyclin-dependent kinases (CDKs) are the two
critical classes of molecules involved in the regulation of
cell-cycle progression. These proteins form an heterodimer
in which cyclins are the regulatory subunits and CDKs are
the catalytic subunits; when the complex is activated from
externalsignals,CDKsactivateorinactivatedownstreamtar-
get proteins to orchestrate coordinated entry into the next
p h a s eo ft h ec e l lc y c l e[ 21].
In normal cells, CDKs are expressed throughout all the
cycle; however, each cyclin protein has a restricted period of
expression, and this limited expression of each cyclin protein
is due to cell-cycle-dependent regulation of both cyclin gene
transcription and protein degradation.
The cyclin/CDK complex is regulated by a number of
phosphorylation and dephosphorylation events, resulting
eitherinactivationorinhibitionofkinaseactivity[22]:phos-
phorylation is carried out by cyclin-activating kinase (CAK),
and dephosphorylation is mediated by members of the Cell
Division Cycle 25 family (Cdc25) of dual-speciﬁcity pro-
tein phosphatases. The mammalian Cdc25 family consists
of three members: Cdc25A, Cdc25B, and Cdc25C. Cdc25A
promotes entry into S phase by acting on cyclin A/CDK2
and cyclin E/CDK2 and is required for DNA replication [23–
26]. Cdc25B activation occurs during S phase and peaks
during the G2 phase [27, 28]. Both Cdc25B and Cdc25C
play roles in the G2/M transition. Cdc25C dephosphorylates
cyclin B1/cdc2 and is essential for progression through the
G2/M phase of the cell cycle [29].
Decision to enter S phase is made in mid-to-late G1 and
is called the restriction point.M o l e c u l a rs w i t c hf r o mG 1t o
S phase and targets of the G1 phase cyclin/CDK complexes
are members of the retinoblastoma protein (RB) family: RB,
p107, and p130 [30]. RB can function as either a transcrip-
tional repressor or a transcriptional activator depending on
its phosphorylation state and the proteins with which it
binds: when hypophosphorylated and bound to the E2F
family of transcription factors, it works as a transcriptional
repressor [31]. The E2F family mediates transcription of
genes required for DNA synthesis, including cyclin E, cyclin
A, cyclin B, dihydrofolate reductase, and thy-midine kinase
[32]. Sequential phosphorylation of RB by cyclin D/CDK4/6
and cyclin E/CDK2 complexes inhibits the repressor activity
of RB, as it results in the dissociation of E2F and RB, and
S phase entry. As cells progress into S phase, maintenance
of RB hyperphosphorylation is necessary for the successful
completion of DNA replication [33]. Mu-tations that aﬀect
the RB signaling pathway have been iden-tiﬁed in the major-
ity of human cancers [34].
CDKs are also regulated by a group of functionally
related proteins called CDK inhibitors. The CDK inhibitors
are grouped into two families: the INK4 inhibitors (p16,
p15, p19, and p18) and the Cip/Kip inhibitors (p21, p27,
and p53). The INK4 family speciﬁcally inhibits CDK4 and
CDK6 activity during the G1 phase of the cell cycle, while
the Cip/Kip family inhibits CDK activity during all phases of
the cell cycle. Both families of these inhibitors can arrest cells
in the G1 phase of the cell cycle by inhibiting the activities
of CDKs and preventing their ability to phosphorylate and
inactive RB and other RB-family proteins [21].
The Sp h a s eof the cell cycle is the stage in which occurs
the DNA replication. At the beginning of the S phase, each
chromosome is composed of one coiled DNA double helix
molecule; at the end of this stage, each chromosome has
two identical DNA double helix molecules and therefore is
composed of two sister chromatids. During this phase, the
centrosome is also duplicated [35, 36]. It is proposed that
replication origins are in two diﬀerent states during the cell
cycle: one during G1 phase, before DNA replication begins,
when a multiprotein prereplicative complex (pre-RC) assem-
bles on the origin. The second state exists from the initiation
of S phase to the end of M phase, when a postreplicative
complex (post-RC) is present at the replication origins.
Initiator proteins required for pre-RC formation include
the origin recognition complex (ORC), MCM proteins (that
forms the replicative helicase), Cdc6, and Cdt1 (required to
load MCM proteins on chromatin) [37–40]. This multipro-
teincomplexisactivatedattheG1/Stransition;subsequently,
DNA replicating proteins such as DNA polymerase α and β
are recruited to initiation sites [27]. An increase in CDK2
and hcdc7 activity at the G1/S transition triggers initiation
and converts the origin to the post-RC state. The CDK cycle
controls the two states at replication origins, couples the ini-
tiationofSphasetothecompletionofMphase,andprevents
rereplication events from occurring during a single round of
the cell cycle [41, 42].
As cells enter into G2 phase, the cyclin B/cdc2 complexes
are kept inactive by phosphorylation. At the end of this
phase, the cells are ready to enter into mitosis, and cyclin
B/cdc2 complexes are activated by dephosphorylation [43].
The enzyme that dephosphorylates and activates cdc2 at
the end of G2 and initiates mitosis is Cdc25C [44]. This
transition point is one of the most important during the
progression of cell cycle, and diﬀerent mechanisms control
this stage. Cdc25C is localized in the cytoplasm during
interphase and enters the nucleus just before mitosis. Also
cyclin B1 is in the cytoplasm during S phase and G2 phase
and is translocated to the nucleus at the beginning of mitosis
[45]. It is thought that the precise regulation of cyclin B1
localization prevents premature mitosis during interphase,
while allowing regulated access of cyclin B1/cdc2 complexes
to their nuclear substrates at the onset of mitosis. Although
less well understood, Cdc25B and A/Cdc2 also play a role at
the mitotic transition.
As cells enter mitosis, phosphorylation of key compo-
nents causes signiﬁcant changes in the architecture of the
cell, and this phosphorylation is due mainly to cyclin B/cdc2
activity [46]. This complex induces changes in the micro-
tubule network, in the actin microﬁlaments, and in the
nuclear lamina [47]. Other cyclin B/cdc2 substrates includePathology Research International 3
histone H1 and microtubule-associated proteins such as
MAP4, MAP2, and stathmin [48]. The family of polo-like
proteinkinases(Plks)alsoplaysacriticalroleinseveralmito-
ticevents[49].Theyarecriticalfortheformationofabipolar
spindle. It is proposed that Plks initiate the onset of mitosis
by activating Cdc25C. Plks are also important regulators of
mitotic exit.
Mitotic exit requires sister chromatid separation, spindle
disassembly, and cytokinesis. The initiation and coordina-
tion of these processes are controlled by degradation of key
regulatory proteins. The mediator of this protein destruction
isamultisubunitproteincalledtheanaphase-promotingcom-
plex (APC) or cyclosome [50]. Key APC substrates are the
mitotic A- and B-type cyclins. Cyclin A is degraded in meta-
phase, whereas B-type cyclins are degraded when cells enter
anaphase [51]. Cyclin B1 destruction starts as soon as the
last chromosomes are aligned on the metaphase plate and
is complete by the end of metaphase [52]. Another group
of APC substrates are proteins that function as anaphase in-
hibitors. During G2, sister chromatids are held together by
proteins called cohesins, which require inactivation by APC
for anaphase initiation [53]. Overall, the APC regulates two
diﬀerent steps in mitosis. First, sister chromatid separation
is triggered by destruction of the anaphase inhibitors, after
which spindle disassembly and mitotic exit are initiated by
the degradation of mitotic cyclins. These two steps allow the
cell to couple the exit from mitosis to the prior completion
of anaphase.
3. Cell-CycleCheckpoint
Cell-cycle checkpoints are signal transduction pathways mon-
itoring the successful completion of events in one phase
of the cell cycle before proceeding to the next phase. Cell-
cycle checkpoints contain sensor proteins that scan chrom-
atin for partially replicated DNA, DNA breaks, or other
abnormalities. Sensor proteins are thought to translate
DNA-derived stimuli into biochemical signals that modulate
speciﬁc downstream target proteins and activate signaling
pathways involved in DNA repair and cell-cycle arrest [54].
Further, when cellular damage is irreparable, checkpoint sig-
naling could eliminate potentially hazardous cells by per-
manent cell-cycle arrest or apoptosis.
Thephysiologicalrelevanceofthesesignalingpathwaysis
supportedbytheirevolutionaryconservationandtheﬁnding
that the major consequence of their alteration in humans is
tumorigenesis [54]; in fact, the loss of cell-cycle checkpoints
isauniversalalterationidentiﬁedinhumancancer.Although
numerous genetic alterations can result in loss of normal
checkpoints, the hope is that common strategies will be
developed against a wide variety of cancers.
3.1. G1/S Phase Checkpoint. The G1 cell-cycle checkpoint
prevents damaged DNA from being replicated and is the best
understood checkpoint in mammalian cells. Progression of
cells through early G1, across the restriction point into late
G1andthenintoSphase,requiresthecoordinatedregulation
of multiple positive and negative factors [55]. Cyclin D-
CDK4/6 complexes promote early G1 progression, but cyclin
E (or cyclin A)-CDK2 (or CDK1) activity is required to in-
active RB by hyperphosphorylation to transit the restriction
point into late G1 phase [56]. RB inactivation results in re-
lease of E2F transcription factors and induction of late-G1-
speciﬁc genes, including dihydrofolate reductase (DHFR),
Emi1, and cyclin A [57]. Cyclin A-associated kinase activity
is required to initiate DNA synthesis, prevent rereplication,
and enter mitosis.
Although cyclin A is transcriptionally induced by E2Fs at
the restriction point, cyclin A protein does not accumulate
until the late G1/S phase transition due to ubiquitination
by the anaphase promoting complex (APC) and subsequent
proteolysis by the 26S proteasome. APC is active throughout
G1 phase by association with Cdh1 (APCCdh1), an activator
that confers substrate speciﬁcity [58]. Prior to initiation of
S phase, APCCdh1 is inactivated by the binding of Emi1 to
Cdh1, resulting in stabilization of cyclin A, activation of cy-
clin A-associated kinase activity, and subsequentinactivation
of Cdh1 by phosphorylation [59]. Thus, tight regulation of
cyclin E- and A-associated kinase activity results in a coordi-
nated G1 cell-cycle progression [60].
If DNA is damaged, the G1/S checkpoints prevent transi-
tion of cells into S phase. Due to its essential and rate-
limiting role in G1/S transition, cyclin E/CDK2 is a key
targetfortheDNAdamagecheckpoint[21].DamagetoDNA
inhibits the action of CDK2 thus stopping the progression
of the cell cycle until the damage can be repaired. If the
damage is so severe that it cannot be repaired, the cell self-
destructs by apoptosis. It is proposed that after exposure of
cells to UV or IR, the level of Cdc25A phosphatase rapidly
decreases. Cdc25A removes the inhibitory phosphorylation
on CDK2 that is required for G1/S transition. After IR or UV
exposure, Cdc25A is rapidly phosphorylated by Chk2 and
Chk1, respectively. Chk-mediated phosphorylation triggers
accelerated turnover of Cdc25A and thus inhibition of
CDK2 [61]. An endpoint of this checkpoint signaling is
inhibition of CDK2-dependent loading of Cdc45 onto the
DNAprereplicationcomplexesandthusinhibitionofSphase
[62].
Another important target for checkpoint signaling in
cells that are in G1/S transition before the restriction point
is the p53 tumor suppressor protein [63]. In normal, non
stressed cells, p53 protein has short half-life as result of the
rapid MDM2-mediated degradation of the protein after syn-
thesis [64, 65].
After exposure of cells to stress, p53 phosphorylation
changes and protein levels increase signiﬁcantly. Transduc-
ers that are required for p53-mediated maintenance of
G1 checkpoint arrest are the same as those required for
activation of the checkpoint, namely, the ATM/ATR and
Chk2/Chk1kinases. Among the genes regulated by p53, the
CDK-inhibitor p21WAF1/Cip1 plays a central role in G1
checkpoint by inhibiting CDKs that are essential for entry
into S phase [66–68]. Thus, although ATM/ATR-mediated
signaling can phosphorylate key targets Cdc25A and p53
within minutes after DNA damage, the impact of the sig-
naling pathways regulated by Cdc25A and p53 on CDK24 Pathology Research International
activity and G1/S blockage are separated in time, due to the
dependence of p53 signaling on transcription and protein
synthesis.
Human cells also have evolved additional mechanisms to
prolong a G1 cell-cycle checkpoint arrest. For example, after
exposure of keratinocytes and melanocytes to physiological
doses of UV radiation, there is an increase of the CDK-in-
hibitor p16INK4a [69]. This factor acts as tumor suppressor
which inhibits the activities of cyclin D-dependent kinases,
CDK4 and CDK6, and regulates the activities of RB [70].
Given the direct role that CDK-inhibitors play in regulation
of the G1/S transition, it is not surprising that CDK-inhi-
bitor function is often compromised in human tumors. The
p16INK4A gene is the frequent target of mutations that
ablate its function, including point mutations, promoter
methylation, or homozygous deletions [71]. Likewise, many
human breast cancers have reduced p27Kip1 protein expres-
sion or aberrant subcellular localization of the protein that
has been correlated with more aggressive tumors [72, 73].
3.2. S Phase Checkpoint. The S phase checkpoint monitors
cell-cycle progression and decreases the rate of DNA syn-
thesis following DNA damage. The responses of cells that
are already in S phase at the time of the DNA damage will
be critical for optimal outcome of the cell. These cells must
respondvirtuallyinstantaneouslytohaltinitiationofnewre-
plication forks throughout S phase, and the ﬁrst action to
prevent wrong DNA synthesis is the activation of the ATM
(ataxia telangiectasia mutated) and/or ATR (ATM and Rad3-
related) protein kinase. Both of these proteins belong to a
structurally unique family of serine-threonine kinases, but
they generally respond to distinct types of DNA damage.
ATM is the primary mediator of the response to DNA
double strand breaks (DSBs) that can arise by exposure to
ionizing radiation (IR) [74]. For responses to other types of
DNA damage, such as base damage caused by exposure to
ultraviolet light or alkylating agents, the ATR kinase appears
tobeimportantforinitiatingtherelevantsignaltransduction
pathways [75].
OnceATMorATRhasbeenactivatedbytheintroduction
of DNA damage, these protein kinases begin to phosphory-
late substrates to help the cell arrest cell-cycle progression
or repair DNA. As discussed previously, the phosphorylation
of p53, MDM2, and Chk2 by ATM following DNA damage
contributes to the arrest of cells in G1 before the restriction
point. Among the proteins phosphorylated by ATM that
contribute to arrest of cells in S phase are Nbs1, Brca1,
SMC1, and FAncD2 [76–79]. The importance of this process
in cancer formation in humans is suggested by the fact
that many of these genes are mutated in familial cancer
syndromes.Forexample,thecancersusceptibilitysyndromes
Ataxia-telangiectasia, Nijmegen breakage syndrome, Fan-
coni’s anemia, and familial breast/ovarian carcinoma syn-
drome are caused by inherited mutations in ATM, Nbs1,
FAncD2, and Brca1, respectively.
3.3. G2 Checkpoint. In addition to activation of the G1/S and
S phase checkpoints, DNA damage also activates checkpoint
arrest in G2 to prevent the passage of DNA lesions to two
daughtercellsduringmitosis.Atthisstage,entryintomitosis
is controlled by the activity of the cyclin-dependent kinase
Cdc2. Maintenance of the inhibitory phosphorylations on
Cdc2isessentialforG2checkpointactivation.ATMandATR
indirectly modulate the phosphorylation status of these sites
in response to DNA damage. These DNA damage checkpoint
pathways all share common upstream signaling pathways
made up of the ATM/ATR transducer and Chk2/Chk1
eﬀector kinases [80].
Activation of the G2 checkpoint after genotoxic stress
involves ATM-mediated phosphorylation and activation of
the Chk1 and Chk2 kinases [81, 82]. It is proposed that
direct inhibition of Cdc25 activity by Chk1 is suﬃcient for
proﬁcient checkpoint regulation of Cdc25 and that Cdc25C
might be inhibited by another upstream kinase, Plk1 [83].
The activity of Plk1 is inhibited in the G2 phase of human
tumorcellsexposedtoionizingradiation,camptothecin,and
doxorubicin. Further, expression of a mutant Plk1 in which
residues necessary for Plk1 activation are altered, prevents
Plk1 inactivation, and leads to G2 override in cells treated
with doxorubicin [84].
In addition to a role in G1/S checkpoint function, p53-
mediated signaling plays an integral role in maintenance of
the G2 checkpoint delay after activation of the checkpoint.
p53 is believed to exert G2 checkpoint responses through
transcriptional upregulation of the downstream target genes
p21, 14-3-3, and GADD45. Similar to its regulation of the
cyclin D1/cdk4,6 or cyclin E/cdk2 complexes at the G1/S
checkpoint, p21 can bind to and inhibit the cyclin B1/cdc2
complex and inhibit cyclin-activated kinase-mediated cdc2
activation [85]. The p53-dependent increase in 14-3-3-
modulates the subcellular localization of the cyclin B1/Cdc2
complex, as the binding of 14-3-3 to cdc2 results in retention
of the kinase in the cytoplasm [86]. The p53-mediated
GADD45-dependent G2 arrest is induced only after speciﬁc
types of DNA damage, as lymphocytes from GADD45
knockout mice failed to arrest after exposure to UV radia-
tion but retained the G2 checkpoint initiated by ionizing
radiation [87].
3.4. Spindle Checkpoint. The mitotic spindle checkpoint
monitors spindle microtubule structure, chromosome align-
ment on the spindle, and chromosome attachment to kine-
tochores during mitosis [88]. The spindle checkpoint delays
the onset of chromosome segregation during anaphase until
any defects in the mitotic spindle are corrected. Unattached
kinetochores are thought to be the source of the checkpoint
signal, and mechanical tension at the kinetochore dictates
whether the checkpoint is initiated or not [89]. Activation of
the spindle checkpoint prevents mitotic progression through
inhibition of the anaphase-promoting complex activator,
Cdc20 [89]. Mediators of the spindle checkpoint pathway
include the Mad2, Bub1, and Bub3 proteins [90]. Mad2
localizes to the kinetochores during prometaphase until
alignment of the chromosomes occurs in metaphase and
regulates mitotic exit by interaction with components of
the APC machinery (such as Cdc20) that mediate anaphasePathology Research International 5
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Figure 1: The cell-cycle clock. The most important proteins involved in cell-cycle regulation are depicted.
entry. Bub1 and Bub3 also localize to kinetochores and regu-
late chromosome/kinetochore interactions, and both are re-
quired for cell-cycle arrest after disruption of microtubule
dynamics during mitosis. Inactivating mutations in Bub1
have been identiﬁed in human colon carcinoma cell lines,
suggesting that disruption of the spindle checkpoint could
occur during tumor progression.
Integral to cell-cycle regulation is the proper coordina-
tion of mitotic exit and subsequent S phase entry. After
DNA synthesis, cells have a tetraploid (4N) DNA content
that is reduced to a diploid (2N) DNA content in each
daughter cell after successful completion of mitosis. Intact
checkpoint pathways are needed to prevent the S phase
entry of cells that have failed to properly segregate their
chromosomes during mitosis. Cells with defective spindle
checkpoint function can exit from mitosis with a 4N DNA
content. These cells can inappropriately continue to the next
cell-cycle division and, in the absence of a functional G1/S
checkpoint, enter S phase with a 4N DNA content; this
process is known as endoreduplication. Endoreduplication
results in the generation of polyploid cells, that is, cells with
a 4N or greater DNA content after mitotic exit. Cells that are
RB-, p53-, p21-, or p16-deﬁcient can endoreduplicate after
microtubule inhibitor treatment [91, 92].
TheG1cell-cycleregulators,however,donotdirectlyreg-
ulate the mitotic arrest induced by microtubule inhibitors;
rather, absence of these proteins allows deregulated CDK2
activity, the precise control of which is required for normal
cells to maintain proper coupling of mitotic exit and S
phase entry [92, 93]. Thus, in addition to playing a role
in checkpoint function after DNA damage, proteins that
mediate the G1/S checkpoint through regulation of cdk2
activity also prevent inappropriate S phase entry after an
abnormal mitotic exit and are critical to proper coordination
of S phase and mitosis.
In Figure 1, the most important cell-cycle molecules in-
volved in cancer pathogenesis and progression are depicted.
4.C ell-C y c leP r ot e insandL ungCanc e r
4.1. Components of the G1 to S Phase Transition in Lung Can-
cers. Concerning lung cancer, most of the studies about the
cell-cycle regulation in this neoplasm have been performed
on the G1/S phase. The retinoblastoma gene family consists
of three members, the product of the retinoblastoma gene
(pRb), which is one of the most studied tumor suppressor
genes, and two related proteins, p130 and p107, which have
been shown to be structurally and functionally similar to
pRb [94]. Sequence analysis of these two proteins shows they
share large regions of homology with pRb, especially in two
discontinuous domains which make up the “pocket region”
[95, 96]. The pocket domain is required for binding the three
members of the Rb-family with several viral transforming
oncoproteins,aswellaswithmembersoftheE2Ffamily[97].
Both p130 and p107, like pRb, display growth suppressive
properties,althoughthegrowtharrestsmediatedbythethree
pocketproteinsarenotidentical.Thissuggeststhat,although
the diﬀerent members of the retinoblastoma gene family
may complement each other, they are not fully redundant6 Pathology Research International
functionally [98, 99]. The Rb pocket proteins (pRb, p107,
and p130) play a critical role in G1/S progression, at least
in part, through binding and inactivation of factors (e.g.,
E2F) that promote transcription of genes required for DNA
replication. Although p130, p107, similarly to pRb, interact
with members of the E2F transcription family and have
similar functional consequences, each pocket protein has
ad i ﬀerent temporal proﬁle of interaction with diﬀerent
E2F/DP1 complexes. The binding of p130 to these complexes
is detected predominantly during GO, 12–15 while that
of p107 is detected during the G1 and S phases [98–
104]. Thus, it is possible to propose a simple model in
which the three members of the retinoblastoma gene family
bind and modulate the activity of the E2F/DP complexes,
as well as other transcription factors. In this model, the
binding is regulated by diﬀerent upstream signals such as
cyclin/cdk complexes or viral oncoproteins. The ﬂexibility
of this pathway could explain the distinct activities of the
three pocket proteins in the regulation of cellular division
and cellular diﬀerentiation. Active (underphosphorylated)
pRb can be inactivated and induced to release transcription
factors when it is hyperphosphorylated (in mid-late G1) by
cyclin/cdk4,6 complexes. In turn, the cyclin/cdk complexes
are negatively regulated by two sets of inhibitors, the p21
family (p21Cip1/Waf1,p 2 7 Kip1, and p57Kip2) which interacts
with all cyclin/cdks and the p16 family (INK4)w h i c h
selectively inhibits the cdk4,6-mediated phosphorylation of
pRb [105].
Disruption of this pathway is a prominent abnormality
in both NSCLC and SCLC, albeit through diﬀerent mech-
anisms. Variances in RB mRNA or protein expression in
terms of absence, reduction in quantity, or alteration in fun-
c t i o nh a v eb e e no b s e r v e di nt h i sn e o p l a s m[ 106–109]. The
function of pRb is inactivated in more than 90% of SCLCs
[110]a sar e s u l to fd i ﬀerent mechanisms including point
mutations and abnormal mRNA expression [111]. Changes
in the other pocket proteins (p107 and p130) have been
detected in a minority of cases [112]. In contrast to SCLC,
themajority ofNSCLCcasesexhibit abnormalities intheup-
stream regulators of the pRb pathway, including inactivation
of p16 [113, 114] through diﬀerent mechanisms [115],
reduced levels of p27Kip [116, 117], and enhanced expression
of cyclin D1 [118]. It is likely that inactivation of cdk4,6
inhibitors (p16) and overexpression of cyclin D1 bypass the
pRb checkpoint allowing progress through G1 into DNA
synthesis [119, 120]. Immunohistochemical analyses of the
RB gene product expression have been performed in malig-
nant tissues from this human neoplasm [121]. Because the
three members of the retinoblastoma protein family exhibit
diﬀerent growth suppressive properties, suggesting that they
are not fully functionally redundant, our research group
investigates their pattern of expression in large group of
specimens of lung cancer, using an immunohistochemical
approach. These Rb-family members displayed distinctive
patterns when compared and contrasted with the diﬀerent
parameters. The highest percentage of undetectable levels in
all the specimens examined and the tightest inverse correl-
ation (P value) with the histological grading and with PCNA
expression in the most aggressive tumor types were found
for pRb2/p130, which may suggest an important role for this
protein in the pathogenesis and progression of lung cancer
[122].
Thetumorsuppressorproteinp53alsoregulatesprogres-
sion through the G1 checkpoint of the cell-cycle. In par-
ticular, p53 is activated in response to DNA damage and
serves to arrest cell-cycle progression in G1 and hence
allow time for DNA repair. The fundamental importance
of p53 in lung cancer is highlighted by the frequency of its
mutations, 80% in SCLC and 50% in NSCLC [123]. It is
recognized that p53 is a point of convergence of a complex
network of signaling pathways that regulate its level in the
cell. In turn, p53 binds to speciﬁc DNA sequences and
transactivatesagroupoftargetgenes(includingthecell-cycle
inhibitorp21Waf1/Cip1),therebyinhibitingcellproliferation
and promoting apoptosis. Recent developments in this area
have focused on the identiﬁcation of p53-related genes such
asp73[124]andintheelucidationoftheirroleinlungcancer
[125, 126]. In Figure 2, exempliﬁcative immunostaining in
non-small-cell lung cancers for the retinoblastoma proteins
family and for p53 are depicted.
While several of the factors involved in regulating cell-
cycle control have been investigated in lung cancer, few
studies have examined multiple factors in the same tumor
series.Ourresearchgrouprecentlysetsupastudytoevaluate
theexpressionofp53,p21,p16,andPCNAproteinsinalarge
series of non-small-cell lung cancers (NSCLCs) to assess the
integrity of cell-cycle checkpoints in these tumors, to evalu-
atethecoexpressionoftheseproteins,and,ﬁnally,toexamine
the relationship between these cell-cycle regulators and
the clinicopathological features of NSCLCs, including their
ability to predict survival in NSCLC patients [127]. When
welookedatthecorrelationbetweenclinicopathologicaldata
and expression of cell-cycle proteins, we found a negative
correlation between lymph nodes status and p21, and p16
expression, suggesting a possible role for these two proteins
in the progression of the disease. Interestingly, no correlation
has been identiﬁed between p16, p21, and p53 expression.
When we investigated by univariate analysis the correlation
between diﬀerent protein expressions and survival, we found
that all the cell-cycle markers analyzed except for PCNA had
a statistically signiﬁcant correlation with survival. This result
isinagreementwithnumerousdatapublishedaboutthecell-
cycle checkpoints investigated in this paper and lung cancer
[128–132]. Surprisingly, when we performed multivariate
analysis, the only immunohistochemical parameter that
resulted to inﬂuence overall survival was p16. This result is
in agreement with the proposed hypothesis that the great
majority of lung cancer samples have inactivated the RB/p16
tumor suppressor pathway. Among the clinical parameters,
tumor staging was the only factor to inﬂuence survival in
multivariate analysis. Finally, we grouped the lung cancer
specimens based on p21 and p16 status. Interestingly, we
found that the group of lung cancer specimens having
both p21 and p16 negative displayed a signiﬁcant shorter
overall survival. Numerous data from the literature suggest
the existence of a functional collaboration between distinct
CDK inhibitor genes [133]. Indeed, it has been recently
demonstrated that cell-cycle inhibition by p16 is associatedPathology Research International 7
(a) (b)
(c) (d)
Figure 2: The immunohistochemical expression of retinoblastoma protein family and p53 in non-small-cell lung cancer. Exempliﬁcative
staining for Rb (a), p107 (b), p130 (c), and p53 (d) are depicted.
with a posttranscriptional induction of p21 and a strong
inhibition of cyclin E-cdk2 kinase activity [134]. Moreover,
it has been shown that members of the p21 family of
proteins promote the association of D-type cyclins with
CDKs by counteracting the eﬀects of p16 molecules [135].
It has been, therefore, proposed that functional cooperation
between diﬀerent cell-cycle inhibitor proteins constitutes
another level of regulation in cell growth control and tumor
suppression. Taking into account the complicated functional
network constituted by the cell-cycle regulator proteins, it
appears evident that knowledge of the level of expression of
these factors, and their coregulation, may be important in
predicting patient clinical response to therapy.
In a diﬀerent study, we determined the prognostic role of
PCNA, p53, p27, pRb/p105, pRb2/p130, Cyclin D1, and p16
expression in a well-deﬁned set of patients who underwent
radical surgical treatment for non-small-cell lung cancer and
had long-term followup [136]. Moreover, we explored the
association of molecular markers with pathologic and clini-
cal characteristics of this lung cancer population. The availa-
bility of the expression status of all tumor markers in the
same set of patients provided a unique opportunity to deter-
mine whether alterations in p53, p27, pRb/p105, pRb2/p130,
Cyclin D1, and p16 expression exert a cooperative or
synergistic eﬀect on lung cancer progression, metastasis,
and survival. Surprisingly, when we performed multivariate
analysis, the only immunohistochemical parameters that
resulted to inﬂuence overall survival were p16, Cyclin D1,
and pRb2/p130. Moreover, we showed that sim-ultaneous
loss of expression of three of these factors, the cyclin D1,
the cyclin-dependent kinase inhibitor p16, and the tumor
suppressor pRb2/p130, identiﬁed a group of patients with
worse prognosis. This result is in agreement with the
proposed hypothesis that the great majority of lung cancer
samples have inactivated the p16/Cyclin D1/retinoblastoma
t u m o rs u p p r e s s o rp a t h w a y[ 137]. Our results demonstrate
detection of an aberrant p53 in a discrete number of the
specimens, which, however, does not correlate with patient
survival in multivariate analysis. This ﬁnding contrasts with
a previous study from our group which reported on 61 non-
small-cell lung cancers and does not clarify the still debated
prognostic role of p53 in lung cancer patients [10]. A recent
study aimed to qualitatively review the association between
p53 alterations and patient outcome by analyzing data from
published papers, through a meta-analysis, showed that p53
mutationisasigniﬁcantmarkerofpoorprognosisinpatients
with lung adenocarcinoma [138]. Finally, we grouped the
lung cancer specimens based on Cyclin D1, pRb2/p130, and
p16 status. Interestingly, we found that the group of lung
cancer specimens having three adverse prognostic factors
displayed a signiﬁcant shorter overall survival. Numerous
data from the literature suggest the existence of a functional
collaboration between distinct CDK inhibitor genes [139].
It has been therefore proposed that functional cooperation
between diﬀerent cell-cycle regulator proteins constitutes
another level of regulation in cell growth control and tumor
suppression [140].
4.2. Components of G2 and M Phases in Lung Tumors. High
levels of cyclin B1 are observed in NSCLC [141]. Cyclin B18 Pathology Research International
has also been reported as a signiﬁcant prognostic factor in
NSCLC in multivariate analysis, suggesting that cyclin B1
expression may be a prognostic marker for these patients.
CDK1 activity is controlled by phosphorylation, and this
process is regulated by the WEE1 and PLK1 kinases. Indeed,
downregulation of WEE1 expression has been reported in
lung tumors [141]. By contrast, elevated levels of PLK1 are
observed in NSCLC and overexpression of PLK1 is a negative
prognostic factor in NSCLC patients [142]. Overexpression
of Aurora A transcript and protein has been reported
in NSCLC and was correlated with poor diﬀerentiation
[143]. Although less extensively studied than Aurora genes,
other mitotic genes display lung cancer-associated altered
expression. They include microtubule-associated proteins
such as TPX2 and TACC3 whose overexpression has been
associated with poor clinical outcome [144].
4.3. Components of Cell-Cycle Checkpoints in Lung Tumors.
CHFR, a mitotic checkpoint gene that delays chromosome
condensation in response to microtubule poisons, has been
described mutated and methylated in NSCLC [145]. Somatic
mutations of ATM that correlate with smoking history and
the presence of DNA repair defects are also detected in
NSCLC [146]. Consistently, downregulation or absence of
CHK2 expression has been reported in NSCLC, mainly due
to hypermethylation of the CHK2 gene promoter [147]. De-
fects in the SAC can lead to premature separation of sister
chromatids and could facilitate chromosomal instability,
which may favor tumor progression. Somatic mutations of
several SAC regulators, such as Bub1 and Mad1,h a v eb e e n
reported in lung tumors, but the eﬀect of these mutations
onmitoticcheckpointsignalinghasnotbeenexamined[148,
149]. Finally, RASSF1A, a key negative regulator for mitosis
progression and well-known tumor suppressor, undergoes
frequent tumor-speciﬁc epigenetic inactivation in a wide
r a n g eo ft u m o r s ,a n de s p e c i a l l yi nl u n gc a n c e r[ 150].
5. Conclusion
In conclusion, all the works mentioned here provide useful
information on the prognosis of newly diagnosed cases of
lung cancer and would allow researchers to recognize a sub-
group of patients with signiﬁcantly improved survival, in
which it could be possible to achieve better response to
therapy.Nevertheless,targetingmultiplecheckpointproteins
may represent a good therapeutic strategy for the develop-
ment of new molecular treatments for lung cancer. The
data presented in this paper support this hypothesis and
strongly suggest further works aimed at investigating the
simultaneous expression ofnumerous cell-cycleregulators in
lung cancer.
References
[1] S. Z¨ ochbauer-M¨ uller, A. F. Gazdar, and J. D. Minna,
“Molecular pathogenesis of lung cancer,” Annual Review of
Physiology, vol. 64, pp. 681–708, 2002.
[2] T .A.D ’A mic o ,T .A.A lo ia,M.B .M oo r eetal.,“P r edictingthe
sites of metastases from lung cancer using molecular biologic
markers,” Annals of Thoracic Surgery, vol. 72, no. 4, pp. 1144–
1148, 2001.
[3] C. Lu, J. C. Soria, X. Tang et al., “Prognostic factors in res-
ected stage I non-small-cell lung cancer: a multivariate anal-
ysis of six molecular markers,” Journal of Clinical Oncology,
vol. 22, no. 22, pp. 4575–4583, 2004.
[4] R. Feld, L. V. Rubinstein, and T. H. Weisenberger, “Sites of
recurrence in resected stage I non-small-cell lung cancer: a
guide for future studies,” Journal of Clinical Oncology, vol. 2,
no. 12, pp. 1352–1358, 1984.
[5] T. A. D’Amico, M. Massey, J. E. Herndon II, M. B. Moore,
a n dD .H .H a r p o l e ,“ Ab i o l o g i cr i s km o d e lf o rs t a g eIl u n g
cancer: immunohistochemical analysis of 408 patients with
the use of ten molecular markers,” Journal of Thoracic and
Cardiovascular Surgery, vol. 117, no. 4, pp. 736–743, 1999.
[6] R. Bordoni, “Consensus conference: multimodality manage-
ment of early- and intermediate-stage non-small cell lung
cancer,” The Oncologist, vol. 13, no. 9, pp. 945–953, 2008.
[7] D. Liu, C. L. Huang, K. Kameyama et al., “E-cadherin
expression associated with diﬀerentiation and prognosis in
patients with non-small cell lung cancer,” Annals of Thoracic
Surgery, vol. 71, no. 3, pp. 949–954, 2001.
[ 8 ] T .A .D ’ A m i c o ,T .A .A l o i a ,M .B .H .M o o r ee ta l . ,“ M o l e c u l a r
biologicsubstagingofstageIlungcanceraccordingtogender
and histology,” Annals of Thoracic Surgery,v o l .6 9 ,n o .3 ,p p .
882–886, 2000.
[9] D. R. Shopland, “Tobacco use and its contribution to early
cancer mortality with a special emphasis on cigarette smok-
ing,” Environmental Health Perspectives, vol. 103, no. 8, pp.
131–142, 1995.
[10] V. Esposito, A. Baldi, A. De Luca et al., “Prognostic value
of p53 in non-small cell lung cancer: relationship with pro-
liferatingcellnuclearantigenandcigarettesmoking,”Human
Pathology, vol. 28, no. 2, pp. 233–237, 1997.
[11] V. Esposito, A. Baldi, A. De Luca et al., “Prognostic role of
the cyclin-dependent kinase inhibitor p27 in non-small cell
lung cancer,” Cancer Research, vol. 57, no. 16, pp. 3381–3385,
1997.
[12] M. Caputi, V. Esposito, A. Baldi et al., “P21 expression in
non-small cell lung cancer: relationship to survival,” The
American Journal of Respiratory Cell and Molecular Biology,
vol. 18, no. 2, pp. 213–217, 1998.
[13] A. M. Groeger, M. Caputi, V. Esposito et al., “Expression of
p21 in non-small cell lung cancer relationship with PCNA,”
Anticancer Research, vol. 20, no. 5, pp. 3301–3306, 2000.
[14] A. Baldi, V. Esposito, A. De Luca et al., “Diﬀerential expres-
sion of Rb2/p130 and p107 in normal human tissues and in
primary lung cancer,” Clinical Cancer Research, vol. 3, no. 10,
pp. 1691–1697, 1997.
[15] V .Esposit o ,A.M.Gr oeger ,L.Deetal.,“Expr essionofsurfac e
proteinreceptorsinlungcancer,”Anticancer Research,vol.22,
no. 6 C, pp. 4039–4044, 2002.
[16] A. M. Groeger, V. Esposito, A. De Luca et al., “Prognostic
valueofimmunohistochemicalexpressionofp53,BAX,BCL-
2 and BCL-Xl in resected non-small cell lung cancer,” Histo-
pathology, vol. 44, no. 1, pp. 54–63, 2004.
[17] B. Vincenzi, G. Schiavon, M. Silletta et al., “Cell cycle altera-
tions and lung cancer,” Histology and Histopathology, vol. 21,
pp. 423–435, 2006.
[18] V. Esposito, M. Campioni, A. De Luca et al., “Analysis of
HtrA1 serine protease expression in human lung cancer,”
Anticancer Research, vol. 26, no. 5, pp. 3455–3460, 2006.
[19] M. Campioni, V. Ambrogi, E. Pompeo et al., “Identiﬁcation
of genes down-regulated during lung cancer progression: aPathology Research International 9
cDNAarraystudy,”JournalofExperimentalandClinicalCan-
cer Research, vol. 27, no. 1, article 38, 2008.
[20] T. C. Mineo, V. Ambrogi, A. Baldi et al., “Prognostic impact
of VEGF, CD31, CD34, and CD105 expression and tumor
vessel invasion after radical surgery for IB-IIA non-small cell
lung cancer,” Journal of Clinical Pathology,v o l .5 7 ,n o .6 ,p p .
591–597, 2004.
[21] H. Matsushime, M. E. Ewen, D. K. Strom et al., “Identiﬁca-
tion and properties of an atypical catalytic subunit (p34PSK-
J3/cdk4) for mammalian D type G1 cyclins,” Cell, vol. 71, no.
2, pp. 323–334, 1992.
[22] C. J. Sherr and J. M. Roberts, “CDK inhibitors: positive
and negative regulators of G1-phase progression,” Genes and
Development, vol. 13, no. 12, pp. 1501–1512, 1999.
[23] S. Jinno, K. Suto, A. Nagata et al., “Cdc25A is a novel
phosphatase functioning early in the cell cycle,” The EMBO
Journal, vol. 13, no. 7, pp. 1549–1556, 1994.
[24] P. Saha, Q. Eichbaum, E. D. Silberman, B. J. Mayer, and
A. Dutta, “p21CIP1 and Cdc25A: competition between an
inhibitor and an activator of cyclin-dependent kinases,”
Molecular and Cellular Biology, vol. 17, no. 8, pp. 4338–4345,
1997.
[25] I. Hoﬀmann, G. Draetta, and E. Karsenti, “Activation of
the phosphatase activity of human cdc25A by a cdk2-cyclin
E dependent phosphorylation at the G1/S transition,” The
EMBO Journal, vol. 13, no. 18, pp. 4302–4310, 1994.
[26] I.BlombergandI.Hoﬀmann,“EctopicexpressionofCdc25A
accelerates theG1/Stransitionandleadstoprematureactiva-
tion of cyclin E- and cyclin A-dependent kinases,” Molecular
and Cellular Biology, vol. 19, no. 9, pp. 6183–6194, 1999.
[27] C. Lammer, S. Wagerer, R. Saﬀrich, D. Mertens, W. Ansorge,
and I. Hoﬀmann, “The cdc25B phosphatase is essential for
the G2/M phase transition in human cells,” Journal of Cell
Science, vol. 111, no. 16, pp. 2445–2453, 1998.
[28] P. A. Garner-Hamrick and C. Fisher, “Antisense phosphoro-
thioate oligonucleotides speciﬁcally down-regulate cdc25B
causingS-phasedelayandpersistentantiproliferativeeﬀects,”
International Journal of Cancer, vol. 76, no. 5, pp. 720–728,
1998.
[29] U. Strausfeld, A. Fernandez, J. P. Capony et al., “Activation
of p34(cdc2) protein kinase by microinjection of human
cdc25C into mammalian cells. Requirement for prior phos-
phorylation of cdc25C by p34(cdc2) on sites phosphorylated
atmitosis,”JournalofBiologicalChemistry,vol.269,no.8,pp.
5989–6000, 1994.
[30] P. D. Adams, “Regulation of the retinoblastoma tumor sup-
pressorproteinbycyclin/cdks,”BiochimicaetBiophysicaActa,
vol. 1471, no. 3, pp. M123–M133, 2001.
[31] W. R. Sellers and W. G. Kaelin, “pRB as a modulator of trans-
cription,” Biochimica et Biophysica Acta, vol. 1288, pp. M1–
M5, 1996.
[32] T. L. Sladek, “E2F transcription factor action, regulation and
possible role in human cancer,” Cell Proliferation, vol. 30, no.
3-4, pp. 97–105, 1997.
[ 3 3 ]E .S .K n u d s e n ,C .B u c k m a s t e r ,T .T .C h e n ,J .R .F e r a m i s c o ,
and J. Y. J. Wang, “Inhibition of DNA synthesis by RB:
eﬀects on G1/S transition and S-phase progression,” Genes
and Development, vol. 12, no. 15, pp. 2278–2292, 1998.
[34] W. R. Sellers and W. G. Kaelin, “Role of the retinoblastoma
protein in the pathogenesis of human cancer,” Journal of
Clinical Oncology, vol. 15, no. 11, pp. 3301–3312, 1997.
[35] J. F. Diﬄey, “Eukaryotic DNA replication,” Current Opinion
in Cell Biology, vol. 6, no. 3, pp. 368–372, 1994.
[ 3 6 ]A .R o w l e y ,S .J .D o w e l l ,a n dJ .F .D i ﬄey, “Recent develop-
ments in the initiation of chromosomal DNA replication: a
complex picture emerges,” Biochimica et Biophysica Acta, vol.
1217, no. 3, pp. 239–256, 1994.
[37] S. P. Bell and B. Stillman, “ATP-dependent recognition of
eukaryotic origins of DNA replication by a multiprotein
complex,” Nature, vol. 357, no. 6374, pp. 128–134, 1992.
[38] B. Stillman, S. P. Bell, A. Dutta, and Y. Marahrens, “DNA re-
plicationandthecellcycle,”CibaFoundationSymposium,vol.
170, pp. 147–156, 1992.
[39] A. Dutta and S. P. Bell, “Initiation of DNA replication in
eukaryotic cells,” Annual Review of Cell and Developmental
Biology, vol. 13, pp. 293–332, 1997.
[40] G. T. Maine, P. Sinha, and B. K. Tye, “Mutants of S. cerevisiae
defectiveinthemaintenanceofminichromosomes,”Genetics,
vol. 106, no. 3, pp. 365–385, 1984.
[41] H. Takisawa, S. Mimura, and Y. Kubota, “Eukaryotic DNA
replication: from pre-replication complex to initiation com-
plex,” Current Opinion in Cell Biology, vol. 12, no. 6, pp. 690–
696, 2000.
[42] J. Wuarin and P. Nurse, “Regulating S phase: CDKs, licensing
and proteolysis,” Cell, vol. 85, no. 6, pp. 785–787, 1996.
[43] B. Stillman, “Cell cycle control of DNA replication,” Science,
vol. 274, no. 5293, pp. 1659–1664, 1996.
[44] W. Krek and E. A. Nigg, “Diﬀerential phosphorylation of
vertebratep34(cdc2)kinaseattheG1/SandG2/Mtransitions
of the cell cycle: identiﬁcation of major phosphorylation
sites,” The EMBO Journal, vol. 10, no. 2, pp. 305–316, 1991.
[45] T. R. Coleman and W. G. Dunphy, “Cdc2 regulatory factors,”
Current Opinion in Cell Biology, vol. 6, no. 6, pp. 877–882,
1994.
[46] A. Hagting, C. Karlsson, P. Clute, M. Jackman, and J. Pines,
“MPF localization is controlled by nuclear export,” The
EMBO Journal, vol. 17, no. 14, pp. 4127–4138, 1998.
[47] E. A. Nigg, “Targets of cyclin-dependent protein kinases,”
Current Opinion in Cell Biology, vol. 5, no. 2, pp. 187–193,
1993.
[48] A. Blangy, H. A. Lane, P. d’H´ erin, M. Harper, M. Kress, and
E. A. Nigg, “Phosphorylation by p34cdc2 regulates spindle
association of human Eg5, a kinesin-related motor essential
for bipolar spindle formation in vivo,” Cell,v o l .8 3 ,n o .7 ,p p .
1159–1169, 1995.
[49] P. K. Sorger, M. Dobles, R. Tournebize, and A. A. Hyman,
“Couplingcelldivisionandcelldeathtomicrotubuledynam-
ics,” Current Opinion in Cell Biology, vol. 9, no. 6, pp. 807–
814, 1997.
[50] S. Llamazares, A. Moreira, A. Tavares et al., “Polo encodes a
protein kinase homolog required for mitosis in Drosophila,”
Genes and Development, vol. 5, no. 12, pp. 2153–2165, 1991.
[51] D. O. Morgan, “Regulation of the APC and the exit from
mitosis,”Nature Cell Biology, vol. 1, no. 2, pp. E47–E53, 1999.
[52] P. Gallant and E. A. Nigg, “Cyclin B2 undergoes cell cycle-
dependent nuclear translocation and, when expressed as a
non-destructible mutant, causes mitotic arrest in HeLa cells,”
Journal of Cell Biology, vol. 117, no. 1, pp. 213–224, 1992.
[53] P. Clute and J. Pines, “Temporal and spatial control of cyclin
B 1d e s t r u c t i o ni nm e t a p h a s e , ”Nature Cell Biology, vol. 1, no.
2, pp. 82–87, 1999.
[ 5 4 ] H .F u n a b i k i ,H .Y a m a n o ,K .K u m a d a ,K .N a g a o ,T .H u n t ,a n d
M. Yanagida, “Cut2 proteolysis required for sister-chromatid
separation in ﬁssion yeast,” Nature, vol. 381, no. 6581, pp.
438–441, 1996.10 Pathology Research International
[55] M. N. Boddy and P. Russell, “DNA replication checkpoint,”
Current Biology, vol. 11, no. 23, pp. R953–R956, 2001.
[ 5 6 ]A .H oa n dS .F .D o w d y ,“ R e g u l a t i o no fG 1c e l l - c y c l ep r o -
gression by oncogenes and tumor suppressor genes,” Current
Opinion in Genetics and Development, vol. 12, no. 1, pp. 47–
52, 2002.
[57] E. Aleem, H. Kiyokawa, and P. Kaldis, “Cdc2-cyclin E
complexes regulate the G1/S phase transition,” Nature Cell
Biology, vol. 7, no. 8, pp. 831–836, 2005.
[58] S. A. Ezhevsky, A. Ho, M. Becker-Hapak, P. K. Davis, and S.
F. Dowdy, “Diﬀerential regulation of retinoblastoma tumor
suppressor protein by G1 cyclin-dependent kinase complexes
in vivo,” Molecular and Cellular Biology, vol. 21, no. 14, pp.
4773–4784, 2001.
[59] G. Fang, H. Yu, and M. W. Kirschner, “Direct binding of
CDC20 protein family members activates the anaphase-pro-
moting complex in mitosis and G1,” Molecular Cell, vol. 2,
no. 2, pp. 163–171, 1998.
[60] J. Y. Hsu, J. D. Reimann, C. S. Sørensen, J. Lukas, and P. K.
Jackson, “E2F-dependent accumulation of hEmi1 regulates S
phase entry by inhibiting APC(Cdh1),” Nature Cell Biology,
vol. 4, no. 5, pp. 358–366, 2002.
[61] C. Lukas, C. S. Sørensen, E. Kramer et al., “Accumulation
of cyclin B1 requires E2F and cyclin-A-dependent rearrange-
ment of the anaphase-promoting complex,” Nature, vol. 401,
no. 6755, pp. 815–818, 1999.
[62] J. Falck, N. Mailand, R. G. Sylju˚ asen, J. Bartek, and J.
Lukas, “The ATM-Chk2-Cdc25A checkpoint pathway guards
against radioresistant DNA synthesis,” Nature, vol. 410, no.
6830, pp. 842–847, 2001.
[63] V. Costanzo, K. Robertson, C. Y. Ying et al., “Reconstitution
ofanATM-dependentcheckpointthatinhibitschromosomal
DNA replication following DNA damage,” Molecular Cell,
vol. 6, no. 3, pp. 649–659, 2000.
[64] M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and
R. W. Craig, “Participation of p53 protein in the cellular res-
ponse to DNA damage,” Cancer Research, vol. 51, no. 23, pp.
6304–6311, 1991.
[65] N. C. Reich and A. J. Levine, “Growth regulation of a cellular
tumour antigen, p53, in nontransformed cells,” Nature, vol.
308, no. 5955, pp. 199–201, 1984.
[66] E. Reihsaus, M. Kohler, S. Kraiss, M. Oren, and M. Monte-
narh, “Regulation of the level of the oncoprotein p53 in non-
transformed and transformed cells,” Oncogene,v o l .5 ,n o .1 ,
pp. 137–145, 1990.
[ 6 7 ]J .W .H a r p e r ,G .R .A d a m i ,N .W e i ,K .K e y o m a r s i ,a n dS .J .
Elledge, “The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases,” Cell,v o l .7 5 ,n o .4 ,
pp. 805–816, 1993.
[68] C. X Deng, P. M. Zhang, J. W. Herper, S. J. Elledge, and
P. Leder, “Mice lacking p21(CIP1/WAF1) undergo normal
development, but are defective in G1 checkpoint control,”
Cell, vol. 82, no. 4, pp. 675–684, 1995.
[69] T. Waldman, K. W. Kinzler, and B. Vogelstein, “p21 is neces-
sary for the p53-mediated G1 arrest in human cancer cells,”
Cancer Research, vol. 55, no. 22, pp. 5187–5190, 1995.
[70] S. Pavey, S. Conroy, T. Russell, and B. Gabrielli, “Ultraviolet
radiationinducesp16(CDKN2A)expressioninhumanskin,”
Cancer Research, vol. 59, no. 17, pp. 4185–4189, 1999.
[71] D. E. Quelle, F. Zindy, R. A. Ashmun, and C. J. Sherr,
“Alternative reading frames of the INK4a tumor suppressor
gene encode two unrelated proteins capable of inducing cell
cycle arrest,” Cell, vol. 83, no. 6, pp. 993–1000, 1995.
[72] N. E. Sharpless and R. A. DePinho, “The INK4A/ARF locus
and its two gene products,” Current Opinion in Genetics and
Development, vol. 9, no. 1, pp. 22–30, 1999.
[73] P. L. Porter, K. E. Malone, P. J. Heagerty et al., “Expression
of cell-cycle regulators p27(Kip1) and cyclin E, alone and in
combination, correlate with survival in young breast cancer
patients,” Nature Medicine, vol. 3, no. 2, pp. 222–225, 1997.
[74] G. Viglietto, M. L. Motti, P. Bruni et al., “Cytoplasmic
relocalization and inhibition of the cyclin-dependent kinase
inhibitor p27kip1 by PKB/Akt-mediated phosphorylation in
breastcancer,”Nature Medicine,vol.8,no.10,pp.1136–1144,
2002.
[75] C. J. Bakkenist and M. B. Kastan, “DNA damage activates
ATM through intermolecular autophosphorylation and di-
mer dissociation,” Nature, vol. 421, no. 6922, pp. 499–506,
2003.
[76] Y.ShilohandM.B.Kastan,“ATM:genomestability,neuronal
development, and cancer cross paths,” Advances in Cancer
Research, vol. 83, pp. 209–254, 2001.
[77] D. S. Lim, S. T. Kim, B. Xu et al., “ATM phosphorylates
p95/nbs1 in an S-phase checkpoint pathway,” Nature, vol.
404, no. 6778, pp. 613–614, 2000.
[78] T. Taniguchi, I. Garcia-Higuera, B. Xu et al., “Convergence
of the fanconi anemia and ataxia telangiectasia signaling
pathways,” Cell, vol. 109, no. 4, pp. 459–472, 2002.
[79] P. T. Yazdi, Y. Wang, S. Zhao, N. Patel, E. Y. Lee, and J. Qin,
“SMC1 is a downstream eﬀector in the ATM/NBS1 branch of
thehumanS-phasecheckpoint,”GenesandDevelopment,vol.
16, no. 5, pp. 571–582, 2002.
[ 8 0 ]B .X u ,A .H .O ’ D o n n e l l ,S .T .K i m ,a n dM .B .K a s t a n ,“ P h o s -
phorylation of serine 1387 in Brca1 is speciﬁcally required
for the Atm-mediated S-phase checkpoint after ionizing
irradiation,” Cancer Research, vol. 62, no. 16, pp. 4588–4591,
2002.
[81] A. Hwang and R. J. Muschel, “Radiation and the G2 phase of
the cell cycle,” Radiation Research, vol. 150, no. 5, pp. S52–
S59, 1998.
[82] Y. Sanchez, S. Wong, R. S. Thoma et al., “Conservation of
the Chk1 checkpoint pathway in mammals: linkage of DNA
damage to Cdk regulation through Cdc25,” Science, vol. 277,
no. 5331, pp. 1497–1501, 1997.
[83] B. Furnari, N. Rhind, and P. Russell, “Cdc25 mitotic inducer
targeted by Chk1 DNA damage checkpoint kinase,” Science,
vol. 277, no. 5331, pp. 1495–1497, 1997.
[84] V. A. J. Smits and R. H. Medema, “Checking out the G2/M
transition,” Biochimica et Biophysica Acta—Gene Structure
and Expression, vol. 1519, no. 1-2, pp. 1–12, 2001.
[85] V. A. J. Smits, R. Klompmaker, L. Arnaud, G. Rijksen, E. A.
Nigg,andR.H.Medema,“Polo-likekinase-1isatargetofthe
DNA damage checkpoint,” Nature Cell Biology, vol. 2, no. 9,
pp. 672–676, 2000.
[86] S. A. Innocente, J. L. A. Abrahamson, J. P. Cogswell, and J.
M. Lee, “p53 regulates a G2 checkpoint through cyclin B1,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 96, no. 5, pp. 2147–2152, 1999.
[87] T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler, and
B. Vogelstein, “14-3-3Sigma is required to prevent mitotic
catastrophe after DNA damage,” Nature, vol. 401, no. 6753,
pp. 616–620, 1999.
[88] X. W. Wang, Q. M. Zhan, J. D. Coursen et al., “GADD45
induction of a G2/M cell cycle checkpoint,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 7, pp. 3706–3711, 1999.Pathology Research International 11
[89] D. J. Burke, “Complexity in the spindle checkpoint,” Current
Opinion in Genetics and Development, vol. 10, no. 1, pp. 26–
31, 2000.
[90] G.J.Gorbsky,“Themitoticspindlecheckpoint,”CurrentBio-
logy, vol. 11, no. 24, pp. R1001–R1004, 2001.
[91] S. H. Khan and G. M. Wahl, “p53 and pRb prevent rerepli-
cation in response to microtubule inhibitors by mediating a
reversible G1 arrest,” Cancer Research, vol. 58, no. 3, pp. 396–
401, 1998.
[92] Z. A. Stewart, S. D. Leach, and J. A. Pietenpol,
“p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity
prevents endoreduplication after mitotic spindledisruption,”
Molecular and Cellular Biology, vol. 19, no. 1, pp. 205–215,
1999.
[93] J. S. Lanni and T. Jacks, “Characterization of the p53-depen-
dent postmitotic checkpoint following spindle disruption,”
Molecular and Cellular Biology, vol. 18, no. 2, pp. 1055–1064,
1998.
[94] M. G. Paggi, A. Baldi, F. Bonetto, and A. Giordano, “The
retinoblastoma protein family incell cycle and cancer,” Jour-
nal of Cellular Biochemistry, vol. 62, no. 3, pp. 418–430, 1996.
[95] M. E. Ewen, Y. Xing, J. B. Lawrence, and D. M. Livingston,
“Molecular cloning, chromosomal mapping, and expression
of the cDNA for p107, a retinoblastoma gene product-related
protein,” Cell, vol. 66, no. 6, pp. 1155–1164, 1991.
[96] X. Mayol, X. Grana, A. Baldi, N. Sang, Q. Hu, and A.
Giordano, “Cloning of a new member of the retinoblastoma
gene family (pRb2) which binds to the E1A transforming do-
main,” Oncogene, vol. 8, no. 9, pp. 2561–2566, 1993.
[97] E. W. Lam and N. B. La Thangue, “DP and E2F proteins:
coordinating transcription with cell cycle progression,” Cur-
rent Opinion in Cell Biology, vol. 6, no. 6, pp. 859–866, 1994.
[98] L. Zhu, S. Van den Heuvel, K. Helin et al., “Inhibition of cell
proliferation by p107, a relative of the retinoblastoma pro-
tein,” Genes and Development, vol. 7, no. 7, pp. 1111–1125,
1993.
[99] P. P. Claudio, C. M. Howard, A. Baldi et al., “p130/pRb2 has
growth suppressive properties similar to yet distinctive from
those of retinoblastoma family members pRb and p107,”
Cancer Research, vol. 54, no. 21, pp. 5556–5560, 1994.
[100] D. Cobrinik, P. Whyte, D. S. Peeper, T. Jacks, and R. A.
Weinberg, “Cell cycle-speciﬁc association of E2F with the
p130 E1A-binding protein,” Genes and Development, vol. 7,
no. 12 A, pp. 2392–2404, 1993.
[101] E. M. Hijmans, P. M. Voorhoeve, R. L. Beijersbergen, L. J.
Van’t Veer, and R. Bernards, “E2F-5, a new E2F family mem-
ber that interacts with p130 in vivo,” Molecular and Cellular
Biology, vol. 15, no. 6, pp. 3082–3089, 1995.
[102] G. Vairo, D. M. Livingston, and D. Ginsberg, “Functional
interaction between E2F-4 and p130: evidence for distinct
mechanisms underlying growth suppression by diﬀerent
retinoblastoma protein family members,” Genes and Devel-
opment, vol. 9, no. 7, pp. 869–881, 1995.
[103] H. Jiang, J. Lin, S. M. Young et al., “Cell cycle gene expression
and E2F transcription factor complexes in human melanoma
cells induced to terminally diﬀerentiate,” Oncogene, vol. 11,
no. 6, pp. 1179–1189, 1995.
[104] S. Shirodkar, M. Ewen, J. A. DeCaprio, J. Morgan, D. M.
Livingston, and T. Chittenden, “The transcription factor E2F
interacts with the retinoblastoma product and a p107-cyclin
A complex in a cell cycle-regulated manner,” Cell, vol. 68, no.
1, pp. 157–166, 1992.
[105] C. Cordon-Cardo, “Mutation of cell cycle regulators: bio-
logical and clinical implications for human neoplasia,”
The American Journal of Pathology, vol. 147, no. 3, pp. 545–
560, 1995.
[106] J. Yokota, T. Akiyama, Y. K. T. Fung et al., “Altered expression
of the retinoblastoma (RB) gene in small-cell carcinoma of
the lung,” Oncogene, vol. 3, no. 4, pp. 471–475, 1988.
[107] J. W. Harbour, S. L. Lai, J. Whang-Peng, A. F. Gazdar, J.
D. Minna, and F. J. Kaye, “Abnormalities in structure and
expression of the human retinoblastoma gene in SCLC,”
Science, vol. 241, no. 4863, pp. 353–357, 1988.
[108] H. J. Xu, S. X. Hu, P. T. Cagle, G. E. Moore, and W. F.
Benedict, “Absence of retinoblastoma protein expression in
primary non-small cell lung carcinomas,” Cancer Research,
vol. 51, no. 10, pp. 2735–2739, 1991.
[109] H. J. Xu, D. C. Quinlan, A. G. Davidson et al., “Altered
retinoblastoma protein expression and prognosis in early-
stage non-small-cell lung carcinoma,” Journal of the National
Cancer Institute, vol. 86, no. 9, pp. 695–699, 1994.
[110] R. Salgia and A. T. Skarin, “Molecular abnormalities in lung
cancer,” Journal of Clinical Oncology, vol. 16, no. 3, pp. 1207–
1217, 1998.
[111] V. Gouyer, S. Gazz´ eri, I. Bolon, C. Drevet, C. Brambilla, and
E. Brambilla, “Mechanism of retinoblastoma gene inactiva-
tion in the spectrum of neuroendocrine lung tumors,” The
American Journal of Respiratory Cell and Molecular Biology,
vol. 18, no. 2, pp. 188–196, 1998.
[112] K. Helin, K. Holm, A. Niebuhr et al., “Loss of the retinoblas-
toma protein-related p130 protein in small cell lung carci-
noma,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.94,no.13,pp.6933–6938,1997.
[113] H. Tanaka, Y. Fujii, H. Hirabayashi et al., “Disruption of the
RB pathway and cell-proliferative activity in non-small-cell
lung cancers,” International Journal of Cancer, vol. 79, no. 2,
pp. 111–115, 1998.
[114] K. Kashiwabara, T. Oyama, T. Sano, T. Fukuda, and T.
Nakajima, “Correlation between methylation status of the
p16/CDKN2 gene and the expression of p16 and Rb proteins
inprimarynon-smallcelllungcancers,”InternationalJournal
of Cancer, vol. 79, no. 3, pp. 215–220, 1998.
[115] S. Gazzeri, V. Gouyer, C. Vour’ch, C. Brambilla, and E.
Brambilla, “Mechanisms of p16(INK4A) inactivation in non
small-cell lung cancers,” Oncogene, vol. 16, no. 4, pp. 497–
504, 1998.
[116] H. Kawana, J. I. Tamaru, T. Tanaka et al., “Role of p27(Kip1)
and cyclin-dependent kinase 2 in the proliferation of non-
small cell lung cancer,” The American Journal of Pathology,
vol. 153, no. 2, pp. 505–513, 1998.
[117] Y. Yatabe, A. Masuda, T. Koshikawa et al., “p27(KIP1) in hu-
man lung cancers: diﬀerential changes in small cell and non-
small cell carcinomas,” Cancer Research,v o l .5 8 ,n o .5 ,p p .
1042–1047, 1998.
[118] A. Marchetti, C. Doglioni, M. Barbareschi et al., “Cyclin D1
and retinoblastoma susceptibility gene alterations in non-
small cell lung cancer,” International Journal of Cancer, vol.
75, no. 2, pp. 187–192, 1998.
[119] G. I. Shapiro, C. D. Edwards, M. E. Ewen, and B. J. Rollins,
“p16(INK4a) participates in a G1 arrest checkpoint in res-
ponse to DNA damage,” Molecular and Cellular Biology, vol.
18, no. 1, pp. 378–387, 1998.
[120] B. Driscoll, L. Wu, S. Buckley, F. L. Hall, K. D. Anderson, and
D. Warburton, “Cyclin D1 antisense RNA destabilizes pRb
and retards lung cancer cell growth,” The American Journal of
Physiology, vol. 273, no. 5, pp. L941–L949, 1997.
[121] M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, and R.
Tateishi, “Retinoblastoma protein expression in lung cancer:12 Pathology Research International
an immunohistochemical analysis,” Oncology, vol. 51, no. 6,
pp. 544–551, 1994.
[122] A. Baldi, V. Esposito, A. De Luca et al., “Diﬀerential
expression of the retinoblastoma gene family members
pRb/p105, p107, and pRb2/p130 in lung cancer,” Clinical
Cancer Research, vol. 2, no. 7, pp. 1239–1245, 1996.
[123] M. L. Agarwal, W. R. Taylor, M. V. Chernov, O. B. Chernova,
a n dG .R .S t a r k ,“ T h ep 5 3n e t w o r k , ”Journal of Biological
Chemistry, vol. 273, no. 1, pp. 1–4, 1998.
[124] C. A. Jost, M. C. Marin, and W. G. Kaelin Jr., “p73 is a human
p53-related protein that can induce apoptosis,” Nature, vol.
389, no. 6647, pp. 191–194, 1997.
[125] M. Mai, A. Yokomizo, C. Qian et al., “Activation of p73 silent
allele in lung cancer,” Cancer Research, vol. 58, no. 11, pp.
2347–2349, 1998.
[126] S. Nomoto, N. Haruki, M. Kondo et al., “Search for
mutations and examination of allelic expression imbalance
of the p73 gene at 1p36.33 in human lung cancers,” Cancer
Research, vol. 58, no. 7, pp. 1380–1383, 1998.
[127] V. Esposito, A. Baldi, B. Vincenzi et al., “Analysis of cell cycle
regulator proteins in non-small cell lung cancer,” Journal of
Clinical Pathology, vol. 57, no. 1, pp. 58–63, 2004.
[128] T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi,
“Prognostic signiﬁcance of p53 alterations in patients with
non-small cell lung cancer: a meta-analysis,” Clinical Cancer
Research, vol. 6, no. 10, pp. 4055–4063, 2000.
[129] T. Shoji, F. Tanaka, T. Takata et al., “Clinical signiﬁcance of
p21 expression in non-small-cell lung cancer,” Journal of Cli-
nical Oncology, vol. 20, no. 18, pp. 3865–3871, 2002.
[130] J. X. Zhou, G. A. Niehans, A. Shar, J. B. Rubins, S. P. Frizelle,
and R. A. Kratzke, “Mechanisms of G1 checkpoint loss in
resected early stage non-small cell lung cancer,” Lung Cancer,
vol. 32, no. 1, pp. 27–38, 2001.
[131] F. J. Kaye, “Rb and cyclin dependent kinase pathways: deﬁn-
ing a distinction between RB and p16 loss in lung cancer,”
Oncogene, vol. 21, no. 45, pp. 6908–6914, 2002.
[132] A. M. Groeger, M. Caputi, V. Esposito et al., “Independent
prognostic role of p16 expression in lung cancer,” Journal of
Thoracic and Cardiovascular Surgery, vol. 118, no. 3, pp. 529–
535, 1999.
[133] D. S. Franklin, V. L. Godfrey, D. A. O’Brien, C. Deng, and
Y. Xiong, “Functional collaboration between diﬀerent cyclin-
dependent kinase inhibitors suppresses tumor growth with
distincttissuespeciﬁcity,”MolecularandCellularBiology,vol.
20, no. 16, pp. 6147–6158, 2000.
[134] J. Mitra, C. Y. Dai, K. Somasundaram et al., “Induction of
p21andinhibitionofcdk2mediatedbythetumorsuppressor
p16,” Molecular and Cellular Biology, vol. 19, no. 5, pp. 3916–
3928, 1999.
[135] D. Parry, D. Mahony, K. Wills, and E. Lees, “Cyclin D-
CDK subunit arrangement is dependent on the availability
of competing INK4 and p21 class inhibitors,” Molecular and
Cellular Biology, vol. 19, no. 3, pp. 1775–1783, 1999.
[136] V.Esposito,A.Baldi,A.DeLucaetal.,“Cellcyclerelatedpro-
teinsasprognosticparametersinradicallyresectednonsmall
cell lung cancer (NSCLC),” Journal of Clinical Pathology, vol.
58, no. 7, pp. 734–739, 2005.
[137] F. J. Kaye, “RB and cyclin dependent kinase pathways: deﬁn-
ing a distinction between RB and p16 loss in lung cancer,”
Oncogene, vol. 21, no. 45, pp. 6908–6914, 2002.
[138] V. Esposito, A. De Luca, A. Baldi et al., “Altered expression of
p53 and Rb tumor suppressor genes in lung cancer: Relation-
ship with survival,” International Journal of Oncology, vol. 9,
no. 3, pp. 439–443, 1996.
[139] A. De Luca, V. Esposito, A. Baldi, and A. Giordano, “The
retinoblastoma gene family and its role in proliferation, dif-
ferentiationanddevelopment,” HistologyandHistopathology,
vol. 11, no. 4, pp. 1029–1034, 1996.
[140] J. Geradts, K. M. Fong, P. V. Zimmerman, R. Maynard, and
J. D. Minna, “Correlation of abnormal RB, p16(ink4a), and
p53 expression with 3p loss of heterozygosity, other genetic
abnormalities,andclinicalfeaturesin103primarynon-small
cell lung cancers,” Clinical Cancer Research, vol. 5, no. 4, pp.
791–800, 1999.
[141] T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, and H. Kuwano,
“The clinical signiﬁcance of Cyclin B1 and Wee1 expression
in non-small-cell lung cancer,” Annals of Oncology, vol. 15,
no. 2, pp. 252–256, 2004.
[142] G. Wolf, R. Elez, A. Doermer et al., “Prognostic signiﬁcance
of polo-like kinase (PLK) expression in non-small cell lung
cancer,” Oncogene, vol. 14, no. 5, pp. 543–549, 1997.
[143] H. T. Xu, L. Ma, F. J. Qi et al., “Expression of serine threonine
kinase 15 is associated with poor diﬀerentiation in lung
squamous cell carcinoma and adenocarcinoma,” Pathology
International, vol. 56, no. 7, pp. 375–380, 2006.
[144] C. K. Jung, J. H. Jung, G. S. Park, A. Lee, C. S. Kang, and K. Y.
Lee, “Expression of transforming acidic coiled-coil contain-
ing protein 3 is a novel independent prognostic marker in
non-small cell lung cancer,” Pathology International, vol. 56,
no. 9, pp. 503–509, 2006.
[145] G. Mariatos, J. Bothos, P. Zacharatos et al., “Inactivating
mutations targeting the chfr mitotic checkpoint gene in hu-
man lung cancer,” Cancer Research, vol. 63, no. 21, pp. 7185–
7189, 2003.
[146] L. Ding, G. Getz, D. A. Wheeler et al., “Somatic mutations
aﬀect key pathways in lung adenocarcinoma,” Nature, vol.
455, no. 7216, pp. 1069–1075, 2008.
[147] P. Zhang, J. Wang, W. Gao, B. Z. Yuan, J. Rogers, and E. Reed,
“CHK2kinaseexpressionisdown-regulatedduetopromoter
methylationinnon-smallcelllungcancer,”MolecularCancer,
vol. 3, article 14, 2004.
[148] A. Gemma, M. Seike, Y. Seike et al., “Somatic mutation of
the hBUB1 mitotic checkpoint gene in primary lung cancer,”
Genes Chromosomes and Cancer, vol. 29, no. 3, pp. 213–218,
2000.
[149] S. Nomoto, N. Haruki, T. Takahashi et al., “Search for in vivo
somatic mutations in the mitotic checkpoint gene, hMAD1,
in human lung cancers,” Oncogene, vol. 18, no. 50, pp. 7180–
7183, 1999.
[150] A. Agathanggelou, W. N. Cooper, and F. Latif, “Role of the
Ras-association domain family 1 tumor suppressor gene in
human cancers,” Cancer Research, vol. 65, no. 9, pp. 3497–
3508, 2005.